AbbVie has today announced that it is set to acquire Gilgamesh Pharmaceuticals’ lead candidate, GM-2505 (aka bretisilocin, a serotonergic psychedelic), which is under development for major depressive disorder (MDD). Under the terms of the deal, the large pharmaceutical company will acquire the bretisilocin program for up to $1.2 billion, including an upfront payment and development milestones…
